...
首页> 外文期刊>The FASEB Journal >Diuresis and reduced urinary osmolality in rats produced by small-molecule UT-A-selective urea transport inhibitors
【24h】

Diuresis and reduced urinary osmolality in rats produced by small-molecule UT-A-selective urea transport inhibitors

机译:小分子UT-A选择性尿素转运抑制剂产生的大鼠利尿和尿渗透压降低

获取原文
获取原文并翻译 | 示例
           

摘要

Urea transport (UT) proteins of the UT-A class are expressed in epithelial cells in kidney tubules, where they are required for the formation of a concentrated urine by countercurrent multiplication. Here, using a recently developed high-throughput assay to identify UT-A inhibitors, a screen of 50,000 synthetic small molecules identified UT-A inhibitors of arylthiazole, γ-sultambenzosulfonamide, aminocarbonitrile butene, and 4-isoxazolamide chemical classes. Structure-activity analysis identified compounds that inhibited UT-A selectively by a noncompetitive mechanism with IC50down to ~1 μM. Molecular modeling identified putative inhibitor binding sites on rat UT-A. To test compound efficacy in rats, formulations and administration procedures were established to give therapeutic inhibitor concentrations in blood and urine. We found that intravenous administration of an indole thiazole or a γ-sultambenzosulfonamide at 20 mg/kg increased urine output by 3-5-fold and reduced urine osmolality by ~2-fold compared to vehicle control rats, even under conditions of maximum antidiuresis produced by 1-deamino-8-D-arginine vasopressin (DDAVP). The diuresis was reversible and showed urea salt excretion. The results provide proof of concept for the diuretic action of UT-A-selective inhibitors. UT-A inhibitors are first in their class salt-sparing diuretics with potential clinical indications in volume-overload edemas and high-vasopressin-associated hyponatremias.
机译:UT-A类尿素转运(UT)蛋白在肾小管的上皮细胞中表达,在那里它们是通过逆流增殖形成浓缩尿液所必需的。在这里,使用最近开发的高通量测定法来鉴定UT-A抑制剂,对50,000个合成小分子进行了筛选,确定了芳基噻唑、γ-磺胺并磺酰胺、氨基甲腈丁烯和4-异噁唑胺化学类别的UT-A抑制剂。构效分析鉴定了通过非竞争性机制选择性抑制UT-A的化合物,IC50降至~1μM。分子建模确定了大鼠UT-A上推定的抑制剂结合位点。为了测试大鼠的化合物功效,建立了制剂和给药程序,以在血液和尿液中提供治疗抑制剂浓度。我们发现,静脉注射吲哚噻唑或γ-磺胺磺酰胺20mg / kg与载体对照大鼠相比,尿量增加3-5倍,尿渗透压降低~2倍,即使在1-脱氨基-8-D-精氨酸加压素(DDAVP)产生最大抗利尿的条件下。利尿是可逆的,显示尿素>盐排泄。研究结果为UT-A选择性抑制剂的利尿作用提供了概念验证。UT-A抑制剂是同类产品中首创的节盐利尿剂,具有治疗容量超负荷水肿和高加压素相关低钠血症的潜在临床适应症。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号